Objective: To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.
Introduction
Integrase strand transfer inhibitors (INSTI) are a potent class of antiretrovirals that block the action of integrase, a viral enzyme, which inserts the viral genome into the DNA of the host cell. This class is currently recommended as first-line treatment for antiretroviral-naive adults and children in the United States living with HIV [1, 2] . Although highly effective and well tolerated antiretroviral treatment options continue to increase, pharmacokinetic and safety data on newer agents for use in pregnant women remain sparse.
Pregnant women living with HIV use antiretrovirals for their own health and to prevent perinatal HIV transmission. Physiologic changes during pregnancy may substantially impact medication exposure [3] . Drugs metabolized by the cytochrome P450 3A (CYP3A) enzyme family, such as protease inhibitors, often show decreased exposure during pregnancy [4] [5] [6] . Exposure to other antiretrovirals may be unchanged or even increased during pregnancy [7] [8] [9] [10] [11] [12] [13] . Lower antiretroviral exposure increases the risk of inadequate maternal viral suppression and transmission of HIV to the infant, whereas increased drug exposure may subject mother and child to increased risk of drug toxicities.
Dolutegravir is a second-generation INSTI, primarily metabolized by uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) with minor contributions from CYP3A [14] . Raltegravir, a first-generation INSTI also metabolized by UGT1A1, displayed decreased exposure during pregnancy by 29 and 50% in two prior studies [15, 16] . Several case reports described dolutegravir exposure in pregnancy [17] [18] [19] . One reported pharmacokinetics over 8 h in one pregnant woman, and in cord blood from two women at delivery who were taking dolutegravir 50 mg twice daily [19] . No studies have described dolutegravir pharmacokinetics with standard dosing (50 mg once daily) during pregnancy. The primary objective of this study was to determine dolutegravir 50 mg once daily pharmacokinetics in pregnant and postpartum women living with HIV, and infant washout pharmacokinetics after birth.
Methods
Study population and design IMPAACT P1026s 'Pharmacokinetic Properties of Antiretroviral and Related Drugs during Pregnancy and Postpartum' (ClinicalTrials.gov NCT00042289), is an ongoing nonrandomized, open-label, parallel-group, multicenter, phase IV prospective study. The study recruited pregnant HIV-infected women receiving dolutegravir 50 mg once daily prescribed for clinical care in the United States. Participants had to be stable on their antiretroviral regimen for 2 weeks, and intend to continue the same regimen through 6-12 weeks postpartum. Maternal exclusion criteria were multiple gestation, a clinical or laboratory toxicity necessitating a medication change during the study, and the use of specific medications known to interact with dolutegravir.
Each study site received ethical and local institutional review board approval. All participants gave informed consent prior to study participation. Medications were prescribed by each participant's clinical care provider. Pharmacokinetic sampling was performed during the second trimester, third trimester, and postpartum, if possible. Collected samples were assayed in real time and results reported to each study participant and her clinician.
Infant enrollment occurred immediately after maternal enrollment with maternal consent, with eligibility confirmed at birth. Infant inclusion criteria were birth weight more than 1000 g, singleton delivery and maternal enrollment in P1026s. Infant exclusion criteria were a severe congenital malformation or medical condition that would interfere with study participation as deemed by site clinicians and use of specific medications known to interfere with dolutegravir disposition.
Clinical and laboratory monitoring
Each maternal study visit included monitoring of HIV-1 RNA, CD4 þ lymphocyte cell count, hematology and serum biochemistry. The lower limit of detection for HIV-1 RNA assays performed locally ranged from 50 to 400 copies/ml. All infants received physical examinations after birth and laboratory evaluations were performed if clinically indicated. Adverse events were reported at each study visit and toxicity management was determined by each participant's clinician.
Sample collection
Intensive 24-h pharmacokinetic evaluations occurred at second trimester (20-26 weeks gestation), third trimester (30-38 weeks gestation) and 6-12 weeks following delivery. Requirements prior to pharmacokinetic sampling were self-reported dolutegravir adherence for 2 weeks and consistent dosing times for the last 3 days. Dolutegravir was dosed without regard to meals. On sampling days, the predose sample was drawn and dolutegravir was administered under observation. Postdose samples were drawn at 1, 2, 4, 6, 8, 12 and 24 h. At delivery, cord and maternal blood samples were collected. In infants, four blood samples were collected at 2-10, 18-28, 36-72 h and 5-9 days after birth.
Dolutegravir concentration assays
Dolutegravir samples were analyzed at the IMPAACT Pharmacology Support Laboratory at the University of Alabama at Birmingham using a sensitive liquid chromatography tandem mass spectrometry assay validated to quantitate total dolutegravir concentrations in human plasma samples [20] . Briefly, this method requires only a 20 ml aliquot of human plasma and has a dynamic range of 0.005-10 mg/ml. Samples are subjected to a simple acetonitrile protein precipitation containing a dolutegravir stable isotope as an internal standard. The laboratory adheres to Clinical Laboratory Improvement Amendments (CLIA) and performs standardized interlaboratory testing though the AIDS Clinical Trial Group (ACTG) clinical pharmacology quality assurance and quality control program.
Pharmacokinetic analyses
Dolutegravir maximum, minimum and last plasma concentrations (C max , C min , C 24 ) along with corresponding time points (T max , T min ) were observed directly. Steady-state area under the concentration versus time curve from time 0 to 24 h postdose (AUC 0-24 ) was estimated with the trapezoidal rule. Half-life (t 1/2 ) was calculated as 0.693/l z ; l z is the elimination rate constant derived from the terminal slope of the log concentration versus time curve. For participants with predose concentrations below the assay quantification limit (indicating probable nonadherence), single-dose AUC from time 0 to infinity was estimated as AUC 0-24 plus the C 24 divided by l z . Apparent oral clearance (CL/F) was calculated as dose divided by AUC 0-24 . Undetectable concentrations were set at half the lower limit of quantification to calculate summary statistics. The 50th percentile AUC 0-24 in nonpregnant adults was 53.6 mg h/ml and the minimal exposure target was the 10th percentile AUC 0-24 , 37.5 mg h/ml, which was approximated from published pharmacokinetic parameters [14] .
Statistical analyses
The target sample size was 25 women with evaluable third trimester pharmacokinetic data, with at least 12 who had evaluable second trimester pharmacokinetic data. Each individual woman's dolutegravir exposure during pregnancy was determined in real time, compared with the 50th and 10th percentile AUCs estimated for nonpregnant adult historical controls and reported to each participant's care provider [14] . A stopping criterion to evaluate the adequacy of drug exposure was predefined as six of 25 women (24%; exact 80% confidence limits: 13-38%) falling below the target AUC. The goal was to prevent excess accrual to a cohort with known inadequate exposure. The statistical rationale for this early stopping criterion was previously described [4] .
Descriptive statistics were calculated for pharmacokinetic parameters during each study period. Ninety percentage confidence limits of the geometric mean ratio of dolutegravir pharmacokinetic parameters in the pregnant versus nonpregnant conditions were calculated. If the confidence limits exclude 1.0, the pharmacokinetic exposure parameter is significantly lower (or higher) in one condition than in the other, with one-sided P value of 0.05 (two-sided P value of 0.10). Pharmacokinetic parameters during the second trimester versus postpartum and during the third trimester versus postpartum were also compared within-subjects using the Wilcoxon signed-rank test, with P < 0.10 considered statistically significant. Nominal variables were compared with Fisher Exact (including all participants) and McNemar (paired data only) tests.
Results

Participant characteristics
Twenty-nine pregnant women taking dolutegravir 50 mg once-daily enrolled in the study. Paired postpartum data were available for 12 of 15 women who had second trimester visits, and for 22 who had third trimester visits. Participant demographic and clinical characteristics are summarized in Table 1 . Twenty-nine live born infants had a median (interquartile range; IQR) birth weight of 3090 g (1480-4000). Infant birth characteristics are summarized in Table 1 . All infants were confirmed eligible at birth; none met the infant exclusion criteria. Dolutegravir C max was 26% lower in the second trimester and 25% lower in the third trimester compared with paired postpartum data (P ¼ 0.0098, P ¼ 0.0025). Dolutegravir C 24 was 51% lower in the second trimester and 34% lower in the third trimester compared with paired postpartum data (P ¼ 0.0039, P ¼ 0.0062). Predose concentrations below the quantitation limit were seen in two participants at the postpartum visit, suggesting recent nonadherence.
Dolutegravir pharmacokinetics
Median (IQR) concentrations of dolutegravir in cord blood and maternal plasma at delivery were 1.67 mg/ml (1.17-2.00) and 1.24 mg/ml (0.57-1.68), respectively.
The ratio of cord blood to maternal plasma was 1. 25 (1.07-1.40). In infants after birth, median dolutegravir C max was 1.85 mg/ml (1.42-2.48) at a median 6.9 h (3.5-9.2). Concentrations through 9 days of life for all infants are shown in Table 3 and Fig. 2 . At the final washout sample (between 5 and 9 days of life), all samples still had measurable dolutegravir (>0.005 mg/ml). One of 16 infants providing washout pharmacokinetic data was breast fed but dolutegravir concentration in breast milk was not assayed. Plasma dolutegravir concentrations in this infant were 4.57, 1.94, 1.66 and 0.44 mg/ml at 7, 25, 46 and 150 h after delivery. Excluding the breastfed infant in whom half-life cannot be reliably calculated, the median (IQR) dolutegravir half-life was 32.8 h (25.9-35.9).
Maternal and infant outcomes
Eight women reported grade 3 adverse events. These included low hemoglobin (n ¼ 3), preeclampsia (n ¼ 2), and preterm labor, nausea/vomiting, cesarean wound infection/fever, blurry vision/headache, low albumin and proteinuria (n ¼ 1 for each). In the third trimester, 28 of 28 (100%) of maternal participants had an HIV-1 RNA 19 (3.6-195) Weeks after delivery at postpartum visit 10 (6-
Emtricitabine/maraviroc 1/29 (3.4) HIV-1 RNA at second trimester (copies/ml) <20 (<20-<20) <50 copies/ml 14/14 (100) HIV-1 RNA at third trimester (copies/ml) <20 (<20-42) <50 copies/ml 28/28 (100) HIV-1 RNA at delivery (copies/ml) <20 (<20-870) <50 copies/ml 27/29 (93.1) HIV-1 RNA at postpartum (copies/ml) <20 (<20 50 copies/ml or less. At delivery, 27 of 29 (93%) of maternal participants had an HIV-1 RNA 50 copies/ml or less and one participant had a viral load over 400 copies/ml (Table 1 ). The two women with detectable viral loads at delivery had dolutegravir exposure at the third trimester approximately equal to the median exposure for the group at that time point. They had been receiving dolutegravir for 22 and 42 weeks. One woman had decreased but still detectable HIV-1 RNA at the postpartum visit, and the other woman was undetectable at the postpartum visit. At postpartum pharmacokinetic sampling, 14 of 19 (74%) maternal participants had an HIV-1 RNA 50 copies/ml or less.
Infants were born at a median of 38.9 weeks of gestation (range: 34.9-42.3). Four infants were preterm (<37 weeks gestation), five were small for gestational age, and four were of low-birth weight (<2500 g), with one of those four being very low-birth weight (<1500 g). All were HIV-negative based on best available data, with 24 infants confirmed uninfected and five indeterminate because of incomplete testing.
Clinical abnormalities were noted at or shortly after birth in seven infants. The clinical findings in three of these infants were considered to be normal variants -one each with congenital filum terminale fibrolipoma, two vessel umbilical cord without other abnormalities, and postaxial polydactyly (supernumerary digit). These findings were considered unrelated to dolutegravir exposure. Total anomalous pulmonary venous return was diagnosed in one infant. This infant's mother began dolutegravir treatment during week 16 of gestation and the cardiac abnormality was judged unrelated to dolutegravir exposure. One infant was noted to have increased jitteriness and chin tremors, which resolved over the first months of life; these neurologic findings were considered unrelated to dolutegravir exposure. Renal abnormalities diagnosed by ultrasound in two infants were deemed possibly related to dolutegravir exposure. One infant, whose mother began dolutegravir treatment during week 12 of gestation, had an isolated renal cyst in the left kidney. Another infant, whose mother began dolutegravir treatment during week 11 of gestation, had a multicystic dysplastic right kidney.
Other adverse events were reported in five infants. Two infants had transient low blood glucose shortly after birth. The infant with the multicystic dysplastic right kidney was also diagnosed with cystic fibrosis and experienced numerous adverse events over the first months of life, including anemia, methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, enterovirus bronchiolitis, malnutrition, pleural effusion, pneumonia and respiratory failure. One infant had neonatal abstinence syndrome following maternal opiate use during pregnancy and respiratory failure. A fifth infant was diagnosed with sickle-cell trait on routine newborn screening.
Discussion
Increasing use of INSTIs as first-line treatment regimens among adults living with HIV will lead to more pregnancies occurring in women on dolutegravircontaining regimens. This study is the first to analyze the pharmacokinetics of dolutegravir 50 mg once-daily dosing in a large population of pregnant women. Paired data demonstrated a 29% decrease in dolutegravir AUC 0-24 in the third trimester compared with postpartum. Second trimester AUC 0-24 was also lower than postpartum. Both second and third trimester C max and C 24 were significantly lower than paired postpartum data by 25-51%. The general risk of decreased antiretroviral exposure is failure to suppress viral replication. This study designated sub-therapeutic exposure less than the 10th percentile dolutegravir AUC 0-24 (37.5 mg h/ml) of nonpregnant adults. Significantly fewer participants met this minimum threshold during pregnancy (60% in second trimester, 71% in third trimester) compared with postpartum (100% postpartum). Although all women had HIV-1 RNA less than 50 copies/ml at the time of the second and third trimester pharmacokinetic sampling, two women had detectable viral loads at delivery. One of these women had a lower but still detectable viral load postpartum, whereas the other woman had an undetectable viral load postpartum.
Even though exposure was lower during pregnancy compared with postpartum, median AUC during pregnancy in this study (47-49 mg h/ml) were similar to the reported values in nonpregnant adults (53.6 mg h/ ml) [14] . Also, postpartum AUC and maximum concentrations in this study were higher than reported values in nonpregnant adults; the significant differences seen between pregnancy and postpartum were in part because of the higher than expected dolutegravir exposures postpartum. This increased exposure postpartum has been noted with other antiretrovirals [6, 15, 21] . The postpartum visits were a median of 10 weeks after delivery. This time frame postdelivery may not represent 'nonpregnant adults,' as physiologic changes that could affect pharmacokinetics of medications may happen abruptly or slowly postpartum and can variably rebound in the opposite direction of pregnancy changes. For example, cardiac output takes 6-12 weeks to return to nonpregnant levels, and kidneys usually take 2-3 months (sometimes up to 4 months) to return to normal, nonpregnant function [22] .
Trough concentrations in this study during pregnancy (0.73 and 0.93 mg/ml) were somewhat lower than those reported in nonpregnant adults (1.11 mg/ml). However, even these lower values are still approximately 11-14 times higher than the reported dolutegravir invitro protein-adjusted 90% effective concentrations (EC 90 ) of 0.064 mg/ml [23] . Notably, the Phase I and Phase II studies of dolutegravir found similar high efficacy rates with doses ranging from 10 to 50 mg [23, 24] . Geometric mean trough concentrations with 10 mg once-daily dosing for 10 -14 days are approximately 0.2-0.3 mg/ml [23, 24] . The troughs seen in this study during pregnancy were still about four times higher than those with 10 mg daily doses that have shown similar efficacy to the 50 mg dose in prior clinical studies. During pregnancy, none of the women in this study had dolutegravir concentrations below the quantitative limit of the assay, 0.005 mg/ml, and no infants acquired HIV infection from their mothers.
Dolutegravir metabolism is primarily dictated by UGT1A1 activity with minor CYP3A contributions [14] . UGT1A1 enzymes can be found in the liver, lungs, intestine mucosa, brain, uterus and placenta [25] . Progesterone-induced UGT1A1 expression and the resulting net increase in metabolism, along with increased CYP 3A activity, may explain decreased dolutegravir concentrations during pregnancy [26, 27] . This study found significantly shorter half-lives and decreased trough dolutegravir concentrations during pregnancy compared with postpartum, consistent with significantly increased clearance. However, half-lives are difficult to accurately estimate in a multiple-dose study with sampling in the elimination phase over less than two half-lives. Dolutegravir is highly bound to plasma proteins [14] but may be displaced by increased hormone binding to these proteins in pregnancy or may have higher unbound concentrations because of lower albumin concentrations in pregnancy. The fraction of unbound dolutegravir mediates the therapeutic action of this antiretroviral, but unbound concentrations were not measured in this study. Though this study observed lower total concentrations in pregnancy compared with postpartum, the therapeutic free fraction of dolutegravir may be increased, stable or decreased during pregnancy.
This study determined the washout kinetics of dolutegravir transferred in utero across the placenta in these infants born to mothers receiving dolutegravir during pregnancy. The median ratio of the dolutegravir concentration in cord blood/maternal plasma at delivery was 1.25, suggesting high placental transfer of dolutegravir consistent with another small study [28] . Elimination of dolutegravir in these newborns was prolonged, with a median elimination half-life in 16 infants of 33 h compared with a median maternal postpartum elimination half-life of 13.5 h. These findings are consistent with a case report of dolutegravir pharmacokinetics in a pregnant woman that described a four-fold increase in elimination half-life in the infant compared with the mother [17] .
In neonates, although UGT1A1 is found in equal concentrations to adults, its activity is low at birth and only reaches adult levels at 3.8 months [29] . Furthermore, UGT1A1 metabolism in adults and neonates is highly variable. Raltegravir, another INSTI metabolized by UGT1A1, had highly variable and extremely prolonged elimination in 19 infants [30] . A common indicator of UGT1A1 activity is bilirubin. For instance, infants with UGT1A1 polymorphisms that decrease enzyme activity are at higher risk of hyperbilirubinemia, which can lead to kernicterus [31] . This study did not measure bilirubin in infants so the correlation between dolutegravir elimination and UGT1A1 activity cannot be assessed this way.
Metabolism of dolutegravir by CYP3A may not play a major role in extended dolutegravir elimination half-lives in infants. Neonatal CYP3A7 activity is high at birth and slowly decreases as adult CYP3A4 activity increases; CYP3A5 remains stable throughout development. This may result in stable CYP3A metabolism in infants compared with adults [32] .
Although clinical abnormalities at birth were noted in seven infants, these findings were thought to be unrelated to dolutegravir exposure in five infants. Findings in three infants were considered normal variants. The mother of the infant with total anomalous pulmonary venous return did not start dolutegravir until week 16 of gestation, after cardiac development was complete, and so the cardiac anomaly was judged unrelated to fetal dolutegravir exposure. Renal abnormalities were found on ultrasound in two infants whose mothers began dolutegravir at the end of the first trimester, and these were the only birth abnormalities considered possibly related to dolutegravir exposure. The infant with the multicystic dysplastic kidney was also diagnosed with cystic fibrosis and had several other adverse events thought to be unrelated to dolutegravir exposure because they were consequences of cystic fibrosis. All of the other adverse events were judged not related to in-utero dolutegravir exposure because they were either common newborn events (hypoglycemia), associated with maternal opiate use during pregnancy (neonatal abstinence syndrome) or was a genetic trait (sickle cell trait). Although our sample size is small for assessing adverse fetal effects from in-utero drug exposure, our data are consistent with the lack of adverse fetal effects seen in preclinical reproductive toxicology studies of dolutegravir [14] . Our data are also consistent with the 83 prospective cases of dolutegravir exposure during pregnancy reported so far to the Antiretroviral Pregnancy Registry, which includes two reports of birth defects in 41 infants with first trimester dolutegravir exposure and one report of a birth defect in 42 infants with second trimester exposure [33] .
One limitation of this study is that opportunistic recruitment of women receiving dolutegravir as part of clinical care generally means that these women are responding to and not experiencing adverse effects from this regimen. This selection bias may overestimate positive outcomes and underestimate adverse events. This study was also limited to participants taking dolutegravir 50 mg once-daily, indicated for treatmentnaive or INSTI-naïve patients. Dolutegravir 50 mg is taken twice-daily for patients with specific INSTIassociated resistance mutations or use of a potent inducer of UGT1A1 or CYP3A metabolism. Once-daily and twice-daily dolutegravir have a nonlinear dose-concentration relationship among nonpregnant adults [14] . Therefore, these findings cannot be applied to patients on a twice-daily dolutegravir regimen. Additionally, dolutegravir was taken regardless of food to align with Food and Drug Administration (FDA) label recommendations. However, low-fat meals increase dolutegravir AUC 0-24 by 33%, moderate-fat meals increase AUC 0-24 by 41% and high-fat meals increase AUC 0-24 by 66% [34] . Therefore, dolutegravir dosing in relation to meals may have added greater variability to the pharmacokinetic data and statistical comparisons in this study.
Study limitations in our infant washout analysis included wide sampling windows, sparse pharmacokinetic time points and lack of correlation with bilirubin concentrations. Also, these results cannot be extrapolated to breastfeeding populations. Prior raltegravir studies identified a lag in elimination with raltegravir concentrations first increasing prior to decreasing in newly born infants [30] . Our sampling windows were too wide to capture this effect, so it is not known if dolutegravir also follows this pattern.
In conclusion, exposure in pregnancy is decreased compared with postpartum, but standard once-daily dosing during pregnancy provides exposure well above that needed to suppress viral replication. Women in this study experienced few adverse events and 93% had less than 50 copies/ml of HIV-RNA at delivery. Dolutegravir crosses the placenta easily, resulting in infant concentrations comparable with maternal plasma concentrations. Low UGT1A1 activity at birth may account for the greater than two-fold increase in dolutegravir elimination half-life in infants as compared with postpartum women. Of the clinical abnormalities observed at birth, only two infants with renal abnormalities, exposed to dolutegravir at the end of the first trimester were considered possibly related to dolutegravir exposure. Additional data are needed on the use of dolutegravir in pregnant women to assess infant safety or to assess twice daily dosing. In summary, dolutegravir exposure is decreased in pregnancy compared with postpartum, but remains at therapeutic concentrations during pregnancy with standard once-daily dosing.
